Provincial Clinical Knowledge Topic

ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory

V 1.1
## Revision History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date of Revision</th>
<th>Description of Revision</th>
<th>Revised By</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>January 2019</td>
<td>Topic Complete</td>
<td>See Acknowledgements</td>
</tr>
<tr>
<td>1.1</td>
<td>June 2019</td>
<td>Pre-operative Order Set and Post-operative Order Set amended; updates to linked documents</td>
<td>Christine Fantuz</td>
</tr>
</tbody>
</table>
Important Information Before You Begin

An Alberta Health Services (AHS) Provincial Clinical Knowledge Topic is the evidence-informed clinical best practice standard for a specific patient population. Enhanced recovery after surgery (ERAS) Topic content is based on recommendations from published international guidelines and other evidence, with consideration for current practices at ERAS sites and other clinical standards. Topic information strives to adhere to Institute for Safe Medication Practices (ISMP) safety standards, and align with provincial and national Quality and Safety initiatives and standards, e.g. Health Quality Council Alberta (HQCA), Choosing Wisely, Safer Healthcare Now, and Accreditation Canada. The Topic will be reviewed periodically and updated according to best practice evidence and other clinical recommendations and guidelines.

Clinicians using this Topic should, in consultation with the patient, use independent medical judgement in the context of individual clinical circumstances to direct care.

Guidelines

This Topic is based on the following guidance:


Keywords

- ERAS
- Enhanced recovery
- Major Gynecology
- Surgery
- Adult
Rationale

International ERAS guidelines were developed to improve patient outcomes, accelerate recovery after surgery, and reduce healthcare costs. ERAS is a multimodal approach, with interventions across all stages of surgical care. Refer to Enhanced Recovery After Surgery: A Review.

The international ERAS guidelines were used in the refinement of provincial care pathways for enhancing recovery after surgery. There are AHS ERAS care pathways developed for Breast Reconstruction (not applicable outside of Foothills Medical Centre, Misericordia Community Hospital and Grey Nuns Community Hospital), Colorectal, Cystectomy, Gynecologic Oncology (not applicable outside of Foothills Medical Centre and Royal Alexandra Hospital), Liver, Major Gynecology, Major Head and Neck (not applicable outside of Foothills Medical Centre and University of Alberta Hospital), and Pancreas surgery. These care pathways are detailed in surgery-specific ERAS Topics.

Certain criteria must be met for a patient to be considered for inclusion in an ERAS care pathway. See the Rationale section in each ERAS Topic for specific surgical procedures appropriate for inclusion.

The inclusion criteria (applicable as of May 29, 2018) for the ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory care pathway are

- Adult female surgical patient undergoing scheduled surgery (open, laparoscopic, laparoscopic-assisted vaginal, and vaginal approach) within Alberta for any of the following major gynecology procedures
  - Hysterectomy
  - Unilateral Salpingo-oopherectomy (USO)
  - Bilateral Salpingo-oopherectomy (BSO)
  - Myomectomy
  - Anterior repair
  - Posterior repair (Rectocele, Enterocele)
  - Paravaginal repair
  - Transvaginal Tape (TVT)
  - Sling
  - Uterine suspension
  - Salpingectomy
  - Oopherectomy
  - Colpocleisis/LeFort
  - Vesico-vaginal fistula repair

While all eligible patients should be started on the ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory care pathway, individual patient care plans may need to be modified based on surgical findings or additional procedures. Major Gynecology surgery patients who do not meet the inclusion criteria may still be considered for applicable recommendations in the ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory care pathway. Patients
undergoing gynecologic oncology procedures may be considered for inclusion in the ERAS Gynecologic Oncology Surgery, Adult – Inpatient care pathway.

**Figure #1 ERASAlberta Care Pathway Inclusion Flowchart**

![Flowchart](https://via.placeholder.com/150)

**Goals of Management**

The goals of clinical management for enhancing the recovery of adult patients after scheduled surgery are to

1. Decrease
   - surgical care length of stay (acute and total) with no increase in readmissions or use of emergency, specialty or primary care related to the post-surgical care
   - surgical complications delaying discharge
   - serious surgical complications including reoperations

2. Increase
   - positive surgical care experiences for patients and families, and providers
   - compliance with ERAS recommendations

This can be achieved by engaging patients and families, clinicians and staff in a multidisciplinary evidence-informed ERAS care pathway focused on

- patient preparation that includes pre-operative optimization, an explanation of the surgical procedure, as well as post-operative expectations and goals to maximize patient participation in their surgical care journey
- pre-operative fasting and carbohydrate loading following national anesthesia guidelines
- appropriate prophylaxis to prevent or reduce surgical complications including venous thromboembolism (VTE), surgical site infections, nausea and vomiting
multimodal, opioid-sparing analgesic approaches to improve the management of perioperative pain, nausea and vomiting
management of physiological surgical stress response
maintenance of normothermia
minimally invasive surgical approaches
balanced fluid management
avoidance of, or early removal of drains and tubes
mobilization soon after surgery
stimulation of gut motility
offer of food and drinks soon after surgery with appropriate nutritional supplements

ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory: Recommendations
ERASAlberta recommendations are based on published international ERAS guidelines and other evidence, with consideration for current practices at ERAS sites and other clinical standards. ERAS® Society recommendations are from the Table of Recommendations within ERAS® Society Guidelines. The GRADE® methodology was used to determine quality of evidence and strength of recommendation for each ERAS® Society recommendation.
Note: Careful consideration should be taken with elderly and/or frail patients, particularly in the area of medication management.

Pre-operative information, education and counselling
ERASAlberta Recommendation: Same as the ERAS® Society recommendation below.

ERAS® Society Recommendation: Patients should routinely receive dedicated preoperative counselling.
ERAS® Society Recommendation - Quality of Evidence: Low
ERAS® Society Recommendation - Strength of Recommendation: Strong

Pre-operative optimization
ERASAlberta Recommendation: Same as the ERAS® Society recommendation below with the following additions: increasing exercise pre-operatively may be of benefit. Patients should be screened for nutritional status including weight loss within the previous 6 months. All patients at nutrition risk need an assessment to confirm malnutrition. If a patient is malnourished, an in-depth nutrition assessment, along with treatment, is required by a registered dietitian.
Note: Alcohol abusers refers to patients with alcohol dependency. Patients with alcohol dependency should wean consumption under the care of a qualified healthcare professional.

ERAS® Society Recommendation: Smoking and alcohol consumption (alcohol abusers) should be stopped four weeks before surgery. Anemia should be actively identified, investigated, and corrected preoperatively.
ERAS® Society Recommendation - Quality of Evidence: Smoking (High), Alcohol (Moderate), Anemia (High)
ERAS® Society Recommendation - Strength of Recommendation: Smoking (Strong), Alcohol (Strong), Anemia (Strong)
Pre-operative bowel preparation

**ERAS® Alberta Recommendation:** Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation:** Mechanical bowel preparation should not be used routinely even when bowel resection is planned.
- **ERAS® Society Recommendation - Quality of Evidence:** Moderate
- **ERAS® Society Recommendation - Strength of Recommendation:** Strong

Pre-operative fasting and carbohydrate load treatment

**ERAS® Alberta Recommendation:** Before scheduled procedures, the minimum duration of pre-operative fasting should be 8 hours after a meal that includes meat, fried or fatty foods, 6 hours after a light meal (such as toast and a clear fluid), and 2 hours after clear fluids as per the *Canadian Anesthesiologists’ Society Guidelines to the Practice of Anesthesia - Revised Edition 2019*. Carbohydrate load treatment should occur between 2 and 3 hours prior to the administration of anesthesia.

Note: The AHS Provincial Clinical Knowledge Topic: *Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient* provides recommendations for patients with diabetes mellitus.

- **ERAS® Society Recommendation:** Clear fluids should be allowed up to 2 hours and solids up to 6 hours prior to induction of anesthesia. Carbohydrate loading reduces postoperative insulin resistance and should be used routinely.
- **ERAS® Society Recommendation - Quality of Evidence:** Solids/fluid (High), Carbohydrate loading – insulin resistance outcome (Moderate), Carbohydrate loading – other outcomes (Moderate)
- **ERAS® Society Recommendation - Strength of Recommendation:** Solids/fluid (Strong), Carbohydrate loading (Strong)

Pre-anesthetic medication

**ERAS® Alberta Recommendation:** Patients should not routinely receive long acting sedative medication before surgery.

- **ERAS® Society Recommendation:** Routine administration of sedatives to reduce anxiety preoperatively should be avoided.
- **ERAS® Society Recommendation - Quality of Evidence:** Low
- **ERAS® Society Recommendation - Strength of Recommendation:** Strong

**Venous thromboembolism prophylaxis**

**ERAS® Alberta Recommendation:** Patients should have a sequential compression device (SCD) applied and/or receive pre-operative or intra-operative pharmacological prophylaxis with heparin. Risk assessment is required in accordance with the AHS-Wide Policy Suite – Venous Thromboembolism Prophylaxis (Policy and Guideline). Patients at risk for venous thromboembolism (VTE) while using systemic estrogen products should be evaluated with consideration for patient risk factors, dose and indication for therapy. If a significant risk is identified, patients may be advised to consider a progestin-only alternative or to stop current therapy prior to the date of surgery. Cessation timing should consider withdrawal bleeding, ovulation, risk of pregnancy, etc. Extended prophylaxis should be provided on the
recommendation of a qualified healthcare professional based on the individual risk of the patient.
Note: Refer to the AHS Provincial Clinical Knowledge Topic: VTE Prophylaxis, Adult – Inpatient (link to be added once available).

- **ERAS® Society Recommendation**: Patients at risk of VTE should receive prophylaxis with either LMWH or heparin, commenced preoperatively, combined with mechanical methods. Patients should be advised to consider stopping hormone replacement therapy (HRT) or consider alternative preparations before surgery. Patients should discontinue oral contraception prior to surgery and switch to another form. Patients should wear well-fitting compression stockings and have intermittent pneumatic compression. Extended prophylaxis (28 days) should be given to patients after laparotomy for abdominal or pelvic malignancies.

- **ERAS® Society Recommendation - Quality of Evidence**: Prophylaxis (High but preoperative administration evidence is Moderate), HRT (Low), Oral contraception (High), Compression (High), Extended (High)
- **ERAS® Society Recommendation - Strength of Recommendation**: Prophylaxis (Strong), HRT (Weak), Oral contraception (Strong), Compression (Strong), Extended (Strong)

**Antimicrobial prophylaxis and skin preparation**

**ERASAlberta Recommendation**: Antibiotic provision as per AHS Recommended Drug Regimens for Surgical Prophylaxis in Adult Patients. Hair clipping is preferred if hair removal is mandatory. Chlorhexidine–alcohol is preferred to aqueous povidone-iodine solution for skin cleansing.

**ERAS® Society Recommendation**: Intravenous (IV) antibiotics (1st generation cephalosporin or amoxi–clav) should be administered routinely within 60 minutes before skin incision; additional doses should be given during prolonged operations, and for severe blood loss and obese patients. Hair clipping is preferred if hair removal is mandatory. Chlorhexidine–alcohol is preferred to aqueous povidone-iodine solution for skin cleansing.

- **ERAS® Society Recommendation - Quality of Evidence**: IV antibiotics (High), Hair clipping (High), Skin cleansing (High)
- **ERAS® Society Recommendation - Strength of Recommendation**: IV antibiotics (Strong), Hair clipping (Strong), Skin cleansing (Strong)

**Prevention of post-operative nausea and vomiting (PONV)**

**ERASAlberta Recommendation**: All patients need to be pre-operatively assessed for risk and provided with perioperative PONV prophylaxis accordingly. A multimodal approach to PONV prophylaxis should be adopted in all high risk patients.

- **ERAS® Society Recommendation**: A multimodal approach to PONV with >2 antiemetic agents should be used for patients undergoing gynecologic procedures.
- **ERAS® Society Recommendation - Quality of Evidence**: Moderate
- **ERAS® Society Recommendation - Strength of Recommendation**: Strong

**Standard anesthetic protocol**
ERASAlberta Recommendation: Emphasis is placed on using short acting anesthetic agents with consideration for the use of total intravenous anesthesia (TIVA) instead of inhalation anesthetic. Opioids should be used sparingly and if needed, short acting opioids are recommended.

- **ERAS® Society Recommendation**: Short acting anesthetic agents should be used to allow rapid awakening. A ventilation strategy using tidal volumes of 5 to 7 mL/kg with a positive end-expiratory pressure (PEEP) of 4 to 6 cm H₂O should be employed to reduce postoperative pulmonary complications.
- **ERAS® Society Recommendation - Quality of Evidence**: Short acting agents (Low), Ventilation (Moderate)
- **ERAS® Society Recommendation - Strength of Recommendation**: Short acting agents (Strong), Ventilation (Strong)

**Prevention of intra-operative hypothermia**

ERASAlberta Recommendation: Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation**: Maintenance of normothermia with suitable active warming devices should be used routinely.
- **ERAS® Society Recommendation - Quality of Evidence**: High
- **ERAS® Society Recommendation - Strength of Recommendation**: Strong

**Perioperative fluid management**

ERASAlberta Recommendation: Same as the ERAS® Society recommendation below with the following addition: the enteral route for fluid post-operatively should be used as early as possible, and intravenous fluids should be discontinued as soon as clinically appropriate. Note: Normal saline is sodium chloride 0.9%.

- **ERAS® Society Recommendation**: Very restrictive or liberal fluid regimes should be avoided in favor of euvoelma. In major open surgery and for high risk patients where there is large blood loss (>7 mL/kg) or a systemic inflammatory response syndrome (SIRS) response, the use of advanced hemodynamic monitoring to facilitate individualized fluid therapy and optimize oxygen delivery during the perioperative period is recommended. Intravenous fluids should be terminated within 24 hours after surgery; balanced crystalloid solutions are preferred to 0.9% normal saline.
- **ERAS® Society Recommendation - Quality of Evidence**: Euvolemia (High), Hemodynamic monitoring (Moderate), Postoperative fluid therapy (Moderate)
- **ERAS® Society Recommendation - Strength of Recommendation**: Euvolemia (Strong), Hemodynamic monitoring (Strong), Postoperative fluid therapy (Strong)

**Minimally invasive surgery (MIS)**

ERASAlberta Recommendation: Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation**: MIS is recommended for appropriate patients when expertise and resources are available.
- **ERAS® Society Recommendation - Quality of Evidence**: Morbidity (Low), Recovery (High)
- **ERAS® Society Recommendation - Strength of Recommendation**: Strong
Nasogastric intubation
ERAS Alberta Recommendation: Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation:** Routine nasogastric intubation should be avoided. Nasogastric tubes inserted during surgery should be removed before reversal of anesthesia.
- **ERAS® Society Recommendation - Quality of Evidence:** High
- **ERAS® Society Recommendation - Strength of Recommendation:** Strong

Surgical site drains
ERAS Alberta Recommendation: Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation:** Peritoneal drainage is not recommended routinely in gynecologic/oncology surgery including for patients undergoing lymphadenectomy or bowel surgery.
- **ERAS® Society Recommendation - Quality of Evidence:** Moderate
- **ERAS® Society Recommendation - Strength of Recommendation:** Strong

Urinary drainage
ERAS Alberta Recommendation: Same as the ERAS® Society recommendation below. Note: The urinary catheter may be removed prior to reversal of anesthesia if bladder/ureteric function is not compromised.

- **ERAS® Society Recommendation:** Urinary catheters should be used for postoperative bladder drainage for a short period, preferably <24 hours postoperatively.
- **ERAS® Society Recommendation - Quality of Evidence:** Low
- **ERAS® Society Recommendation - Strength of Recommendation:** Strong

Prevention of post-operative ileus
ERAS Alberta Recommendation: Same as the ERAS® Society recommendation below.

- **ERAS® Society Recommendation:** The use of postoperative laxatives should be considered. The use of chewing gum should be considered.
- **ERAS® Society Recommendation - Quality of Evidence:** Laxatives (Low), Gum (Moderate)
- **ERAS® Society Recommendation - Strength of Recommendation:** Laxatives (Weak), Gum (Weak)

Post-operative analgesia
ERAS Alberta Recommendation: Same as the ERAS® Society recommendation below with the following addition: consideration for thoracic epidural analgesia (TEA) can be made for the opioid tolerant patient with a history of chronic pain. Note: The use of opioid-sparing strategies is recommended.

- **ERAS® Society Recommendation:** A multimodal approach to analgesia should be adopted including use of nonsteroidal anti-inflammatory drugs (NSAIDS)/acetaminophen, gabapentin and dexamethasone (unless contraindications
exist). Vaginal hysterectomy: Paracervical nerve block or intrathecal morphine can be used to reduce pain and opioid consumption. Open general gynecologic surgery: Spinal anesthesia with intrathecal morphine is recommended. Alternatively, thoracic epidural analgesia (TEA) with low concentration local anesthetic solutions with the addition of opiates for 24-48 hours can be considered. Truncal nerve blocks (transversus abdominis plane [TAP] or ilioinguinal) can be recommended where patients have undergone general anesthesia without neuraxial blockade. Continuous wound infiltration (CWI) of local anesthetic can be considered. Major oncologic surgery TEA may be considered but patients frequently require additional IV opioids in addition to TEA to achieve adequate analgesia. Laparoscopic gynecologic/oncology surgery: Lack of evidence makes it difficult to recommend one analgesic intervention over another, however a multimodal approach should be employed.

- **ERAS® Society Recommendation - Quality of Evidence**: Multimodal (High), NSAIDS/acetaminophen (High), Gabapentin (Moderate), Dexamethasone (Low); Vaginal hysterectomy (Low); Open General Surgery: Spinal with morphine (Moderate), TEA (High), Truncal nerve blocks (Moderate), CWI (Moderate); Major Surgery: TEA (Low); Laparoscopic Surgery (Low)
- **ERAS® Society Recommendation - Strength of Recommendation**: Strong; Vaginal hysterectomy (Weak); Open General Surgery: Spinal with morphine (Strong), TEA (Strong), Truncal nerve blocks (Strong), CWI (Strong); Major Surgery: TEA (Weak); Laparoscopic Surgery (Weak)

**Post-operative glucose control**

**ERASAlberta Recommendation**: ERAS elements that reduce metabolic stress should be employed to reduce insulin resistance and the development of hyperglycemia. Insulin therapy to maintain normoglycemia is recommended, if applicable.

Note: The AHS Provincial Clinical Knowledge Topic: *Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient* provides recommendations for patients with diabetes mellitus.

- **ERAS® Society Recommendation**: ERAS elements that reduce metabolic stress should be employed to reduce insulin resistance and the development of hyperglycemia. Perioperative maintenance of blood glucose levels (<180–200 mg/dL) results in improved perioperative outcomes; glucose levels above this range should be treated with insulin infusions and regular blood glucose monitoring to avoid the risk of hypoglycemia.
- **ERAS® Society Recommendation - Quality of Evidence**: Reduce metabolic stress (High), Maintain blood glucose levels (High)
- **ERAS® Society Recommendation - Strength of Recommendation**: Reduce metabolic stress (Strong), Maintain blood glucose levels (Strong)

**Post-operative nutritional care**

**ERASAlberta Recommendation**: Patients should be encouraged to take normal food as tolerated, as soon as awake and alert after surgery. Oral nutritional supplements (ONS) should be used to supplement total caloric and protein intake.

Note: Nutrition intake should be initiated post-operatively as soon as possible.
ERAS® Society Recommendation: A regular diet within the first 24 hours after gynecologic/oncology surgery is recommended.

ERAS® Society Recommendation - Quality of Evidence: High

ERAS® Society Recommendation - Strength of Recommendation: Strong

Early mobilization
ERASAlberta Recommendation: Same as the ERAS® Society recommendation below.
Note: Mobilization to start post-operative day 0.

- ERAS® Society Recommendation: Patients should be encouraged to mobilize within 24 hours of surgery.
- ERAS® Society Recommendation - Quality of Evidence: Low
- ERAS® Society Recommendation - Strength of Recommendation: Strong

Audit outcomes and compliance
ERASAlberta Recommendation: A systematic audit is essential to determine clinical outcomes and measure overall compliance with clinical recommendations. Reporting on patient experience and functional recovery using validated tools may also be useful. Using more evidence-based elements of perioperative care from an ERAS guideline are likely to improve outcomes further.

- ERAS® Society Recommendation: None
- ERAS® Society Recommendation - Quality of Evidence: N/A
- ERAS® Society Recommendation - Strength of Recommendation: N/A

Clinical Decision Support
The ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory Topic is intended to guide clinicians in enhancing surgical care for all patients who meet the inclusion criteria for the ERAS care pathway. The ERAS clinical knowledge and patient information contained within this Topic are intended to be used as a comprehensive package applied to a surgical care population. All recommendations should be applied to all eligible patients. The anticipated benefits of care management are reduced if the care pathway is applied selectively.

Clinical decision support tools relevant to the ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory care pathway include the following

AHS Pre-Operative Fasting and Carbohydrate Loading Prior to Surgical Interventions – Adults Guideline

AHS Recommended Drug Regimens for Surgical Prophylaxis in Adult Patients

AHS Safe Surgery Checklist

AHS Use of Aprepitant (Emend®) for Prevention of Postoperative Nausea and Vomiting (PONV) in Adults

AHS Venous Thromboembolism Prophylaxis Guideline
AHS VTE Prophylaxis Weight-Band Table – please see AHS internal website

**Bugs & Drugs**

**Canadian Anesthesiologists' Society Guidelines to the Practice of Anesthesia - Revised Edition 2019**

**Canadian Nutrition Screening Tool (CNST)**

**Choosing Wisely Canada: Drop the Pre-Op Toolkit**

**Choosing Wisely Canada: Recommendations and Resources, by Specialty**

**Consensus Guidelines for the Management of Postoperative Nausea and Vomiting**

**Eating and Drinking Before Surgery: Patient Instructions**

Other important clinical information relevant to the ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory care pathway can be found in References and Additional Information.

**ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory Pre-operative Order Set**

**Order Set Components**

**Order Set Keywords:** ERAS, Major Gynecology, Pre-admission, Pre-operative, Surgery

**Before Day of Procedure**

**Patient Teaching**

- Teach: provide ERAS material and discuss perioperative patient goals
  - Your Surgery Journey – Patient Guide

Refer to **AHS Pre-Operative Fasting and Carbohydrate Loading Prior to Surgical Interventions - Adults Guideline.** Refer to **MyHealth.Alberta.ca** for specific patient instructions.

- Teach: Eating and Drinking Before Surgery: Patient Instructions – Non-Diabetic

**OR**

Choose ONE:

- Teach: Eating and Drinking Before Surgery: Patient Instructions – Non-Diabetic, Fasting Only
- Teach: Eating and Drinking Before Surgery: Patient Instructions - Diabetic

- Instruct patient to hold __________________ medication(s) ______ days prior to scheduled surgery

**Consults and Referrals**

- Physician: Anesthesia
Screen for nutrition risk: use Canadian Nutrition Screening Tool (CNST)

- Refer to Registered Dietitian if CNST score equals 2 Yes answers

Laboratory Investigations
- Complete Blood Count (CBC) with differential
- PT INR
- PTT
- Creatinine/eGFR
- Electrolytes (Na, K, Cl, CO₂)
- Glucose Random
- Type and Screen
- Red Blood Cells on Standby Request: _______ units Red Blood Cells
- HCG Beta (Blood Test, Pregnancy): within 72 hours prior to surgery

Diagnostic Investigations
- GR Chest, 2 Projections (Chest X-Ray PA and Lateral)
- Electrocardiogram

Day of Procedure

Patient Care
Discuss Goals of Care with patient or alternate decision-maker and complete or update Goals of Care Designation. Refer to AHS Provincial Clinical Knowledge Topic: Advance Care Planning and Goals of Care Designations, All Ages – All Locations.

- Apply sequential compression device (SCD)
- Apply forced-air warming device
- Perineal Clip: AM of surgery

Monitoring
- Vital Signs: AM of surgery
- Weight: AM of surgery
- Blood Glucose Monitoring Point of Care Testing (POCT): AM of surgery
- Urine Test, Pregnancy Point of Care Testing (POCT): AM of surgery

Diet/Nutrition
Refer to AHS Pre-Operative Fasting and Carbohydrate Loading Prior to Surgical Interventions - Adults Guideline.

The minimum duration of pre-operative fasting prior to the administration of anesthesia should be 8 hours after a meal that includes meat or fried or fatty foods, 6 hours after a light meal (such as toast and a clear fluid), 2 hours after clear fluids.7

Pre-operative eating and drinking
- Clinical Communication: Final snack 8 hours prior to scheduled surgery
- Clinical Communication: Clear fluids until 3 hours prior to scheduled surgery
- NPO 2 hours prior to scheduled surgery

Refer to AHS Provincial Clinical Knowledge Topic: Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient. The recommendation is to avoid carbohydrate loading patients with diabetes mellitus until prospective trials have been completed.
Clinicians should use independent medical judgement in the context of individual clinical circumstances and delete the following order if required.

**Pre-operative carbohydrate loading**
- Clear apple juice or cranberry cocktail *(refer to Appendix A)* 500 mL PO 3 hours prior to scheduled surgery. Must be consumed by 2 hours prior to scheduled surgery
  - If patient’s admission is greater than 3 hours prior to scheduled surgery, provide carbohydrate load
- Assess and document last consumption of food and fluids (including carbohydrate load)

**Intravenous Therapy**
- Intravenous Cannula: insert intra-operatively
- Intravenous Cannula: insert pre-operatively, apply saline lock

**Medications**

**VTE Prophylaxis**
Refer to AHS Provincial Clinical Knowledge Topic: VTE Prophylaxis, Adult – Acute Care *(link to be added once available)*. If patient is at increased risk of VTE *(refer to AHS Venous Thromboembolism Prophylaxis Guideline)* consider pre-operative anticoagulant prophylaxis.
- Heparin 5000 units SUBCUTANEOUSLY once pre-operatively

**Antibiotic Prophylaxis**
Antibiotics should be given within 60 minutes prior to incision.
Choose ONE option:

- **Option 1:**
  - ceFAZolin 2 g IV once pre-operatively
  - *For procedures entering the rectum:*
    - ADD
    - metroNIDAZOLE 500 mg IV once pre-operatively

- **Option 2 if patient has ceFAZolin allergy or severe non-IgE mediated reaction to any β-lactam:**
  - gentamicin (1.5 mg/kg) ____ mg IV once pre-operatively
  - AND
  - clindamycin 600 mg IV once pre-operatively

**Analgesics**
Consider dose reduction if patient is elderly.
- Acetaminophen 975 to 1000 mg PO once pre-operatively, to be given 1 hour prior to surgery. Maximum of 4000 mg acetaminophen in 24 hours from all sources

- **Use caution if patient has renal impairment or is at high risk of acute kidney injury.**
- ibuprofen 400 mg PO once pre-operatively, to be given 1 hour prior to surgery

**OR**
- **Use caution if patient has renal impairment or is at high risk of acute kidney injury. If patient has proven history of ulcers or complicated perforation, obstruction, or major bleeding choose celecoxib:**
- celecoxib 400 mg PO once pre-operatively, to be given 1 hour prior to surgery
Antiemetics

If patient has 3 or 4 of the following risk factors for post-operative nausea and vomiting (PONV)\(^8\):

- female gender
- non-smoker
- history of PONV or motion sickness
- post-operative use of opioids

AND patient meets one of the following criteria:

- High risk of developing PONV within 24 hours after surgery AND history of being refractory to other antiemetic treatments
- Risk of medical sequelae of vomiting (i.e. jaw wiring, neurosurgery, upper gastrointestinal surgery)

Choose aprepitant:

- aprepitant 80 mg PO once pre-operatively, to be given 1 hour prior to surgery

Glycemic Management Medications

Refer to AHS Provincial Clinical Knowledge Topic: Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient.

ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory Intra-operative Guidance

Normothermia

- Operating Room temperature at least 20°C
- Monitor patient’s temperature intra-operatively
- Use forced-air warming device for all procedures lasting longer than 30 minutes to achieve/maintain a temperature between 36°C to 38°C throughout the perioperative period
- Use fluid warmers for procedures in which greater than 1 litre fluid is expected to be administered

Post-operative Nausea and Vomiting (PONV) Prophylaxis

- Provide multimodal prophylaxis with consideration to patient’s PONV risk score and administration of pre-operative PONV prophylaxis\(^9\)

Pain Management

- Consider the use of regional anesthesia (transversus abdominis plane [TAP] block or rectus sheath block)
- Use opioids sparingly. If needed, short acting opioids are recommended. Long acting opioids should be avoided. Patients with pre-operative chronic pain may require additional assessment based on their Best Possible Medication History (BPMH). Consider non-opioid analgesia or appropriate opioid-sparing adjuncts

Additional Guidance

- Consider the use of total intravenous anesthesia (TIVA) instead of inhalation anesthetic
- Avoid routine nasogastric intubation
• Fluid therapy goal is to maintain euvolemia. If appropriate, use goal-directed fluid management to guide fluid therapy especially for high risk patients and for patients undergoing surgery with significant intravascular volume losses anticipated
• Avoid use of prophylactic surgical site drains
• Remove indwelling urinary catheter, if applicable, upon completion of procedure or as soon as clinically indicated

ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory Post-operative Order Set

Order Set Components
Order Set Keywords: ERAS, Major Gynecology, Post-operative, Surgery

Admit, Transfer, Discharge
☐ Anticipated Date of Discharge:______________________________________________

Patient Care
Discuss Goals of Care with patient or alternate decision-maker and update Goals of Care Designation, if applicable. Refer to AHS Provincial Clinical Knowledge Topic: Advance Care Planning and Goals of Care Designations, All Ages – All Locations.
✔ Sequential compression device (SCD): discontinue when ambulating well

Monitoring
✔ Vital Signs: assess as per local institutional practices
✔ Opioid Monitoring: monitor as per local institutional practices
✔ Pain Score and Nausea Score: assess at least every 4 hours x 3 days and then every 8 hours
☐ Blood Glucose Monitoring Point of Care Testing (POCT): QID

Activity
✔ Activity as tolerated
  • Post-operative day (POD) 0: stand at bedside, up in chair, walk to doorway and back; activity goal is 2 hours
  • POD 1: up in chair each meal, ambulate at least 3 times daily; activity goal is 4 hours
  • POD 2 until discharge: up in chair each meal, ambulate at least 3 times daily; activity goal is 6 hours

Intake and Output
✔ Intake: assess every 8 hours x 4 days, include strict oral intake
✔ Urine Output: assess every 4 hours for as long as clinically indicated and/or as per bladder catheterization/bladder scanning routine
☐ Bladder Catheterization/Bladder Scanning Routine: conduct as per local institutional practices
✔ Indwelling Urinary Catheter: remove on POD 1 in AM
✔ In and Out Urinary Catheter: insert PRN for urinary retention once indwelling urinary catheter removed
Weight: assess daily x 3 days, start on POD 1

Diet/Nutrition

- Clinical Communication: offer patient oral fluids; intake goal 500 mL on POD 0
- Post-Surgical Transition Diet: start on POD 0
- Regular Diet: start on POD 1
- Regular Diabetic - Adult Diet: start on POD 1

Protein/Calorie Dense Oral Nutritional Supplements

Appropriate when patient is on any type of oral diet including Gluten-free and Diabetic - Adult. Suitable for lactose intolerance but NOT appropriate for dairy allergy. Achieve a supplement intake of 300 kcal/day on POD 0 and 600 kcal/day on POD 1 until discharge.

- Ensure Protein Max: 90 mL PO 3 times daily, start on POD 0 and then 90 mL PO 5 times daily, start on POD 1 until discharge

Wound Care

- Surgical Incisions: assess every 8 hours and PRN
- Vaginal Packing: remove on POD 1 in AM
- Wound Dressing Instructions: ________________________________

Respiratory Care

- Incentive Spirometry: perform every 1 hour while awake
- Oxygen Therapy: titrate to saturation, maintain SpO2 greater than 92%
- Head of Bed: elevate to at least 30 degrees while patient on opioids or epidural

Laboratory Investigations

- Complete Blood Count (CBC) with differential on POD 1 in AM
- Creatinine on POD 1 in AM
- Electrolytes (Na, K, Cl, CO₂) on POD 1 in AM

Intravenous Therapy

- sodium chloride 0.9% lock when patient tolerating oral fluid intake
- lactated ringer’s infusion IV at 50 mL/hour if patient not tolerating oral fluid intake, lock when patient tolerating oral fluid intake

Medications

VTE Prophylaxis

Refer to AHS Provincial Clinical Knowledge Topic: VTE Prophylaxis, Adult – Inpatient (link to be added once available). Refer to AHS VTE Prophylaxis Weight-Band Table (see AHS internal website) if patient has reduced renal function or is less than 40 kg or greater than 100 kg.

- tinzaparin 4500 units SUBCUTANEOUSLY once daily at ______ hours (hh mm), start on POD ______ until discharge

Antiulcer Agents and Acid Suppressants

- pantoprazole EC tab 40 mg PO daily before breakfast until discharge
- ranitidine 150 mg PO BID until discharge

Bowel Stimulation

- Chew gum 3 times daily (minimum 30 minutes each time), as tolerated
Choose ONE:
- magnesium hydroxide 30 mL PO BID, start on POD 1 and discontinue after first bowel movement
- polyethylene glycol 3350 powder 17 g PO daily until discharge, start on POD 1

Analgesics
Consider non-opioid analgesia or appropriate opioid-sparing multimodal analgesia. If needed, short acting opioids are recommended. Long acting opioids should be avoided.
- Follow Anesthesia/Acute Pain Service orders for continuous regional epidural, nerve block therapy and/or patient controlled analgesia (PCA)
- Follow Surgery orders for patient controlled analgesia (PCA)

Prophylaxis Analgesics
Consider dose reduction if patient is elderly.
- acetaminophen 975 to 1000 mg PO every 6 hours x 48 hours and then acetaminophen 975 to 1000 mg PO every 6 hours PRN for pain. Maximum of 4000 mg acetaminophen in 24 hours from all sources
  Use caution if patient has renal impairment or is at high risk of acute kidney injury.
- ibuprofen 400 mg PO every 6 hours x 48 hours and then ibuprofen 400 mg PO every 6 hours PRN for pain

PRN Oral Opioids (for pain not controlled by non-opioid analgesia)
Consider dose reduction if patient is elderly or opiate-naïve.
Choose ONE:
- oxyCODONE 5 to 10 mg PO every 4 hours PRN for pain not controlled by non-opioid analgesia
- HYDROmorphine 1 to 2 mg PO every 4 hours PRN for pain not controlled by non-opioid analgesia

PRN Parenteral Opioids (for pain not controlled by oral opioids, or oral analgesia is contraindicated)
Consider dose reduction if patient is elderly or opiate-naïve.
Choose ONE:
- morphine 1 to 10 mg IV/SUBCUTANEOUSLY every 4 hours PRN for pain not controlled by oral opioids
- HYDROmorphine 0.5 to 2 mg IV/SUBCUTANEOUSLY every 4 hours PRN for pain not controlled by oral opioids

Antiemetics
Consider dose reduction if patient is elderly or has reduced renal function.
Choose ONE option:

Option 1:
Choose ALL:
- ondansetron 8 mg PO/NG (or ODT if difficulty swallowing or active vomiting with no IV access) every 8 hours x 48 hours and then ondansetron 4 mg PO/NG every 8 hours PRN
□ ondansetron 4 mg IV every 8 hours and then ondansetron 4 mg IV every 8 hours PRN if oral dose is not tolerated

AND
□ metoclopramide 10 mg PO/NG/IV/IM every 6 hours PRN

Option 2:
Choose BOTH:
□ metoclopramide 10 mg PO/NG/IV/IM every 6 hours x 48 hours and then metoclopramide 10 mg PO/NG/IV/IM every 6 hours PRN

AND
□ ondansetron 4 mg PO/NG/IV (or ODT if difficulty swallowing or active vomiting with no IV access) every 8 hours PRN. If nausea and vomiting persist after first PRN dose, notify prescriber

Glycemic Management Medications
Refer to AHS Provincial Clinical Knowledge Topic: Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient.

Patient Teaching
□ Teach: double-voiding technique
□ Teach: self-catheterization

Consults and Referrals
□ Physiotherapy
□ Registered Dietitian
□ Social Work
□ Transition Services

Rural Considerations
The ERAS clinical knowledge and patient information contained within each Topic are intended to be used as a comprehensive package to maximize the anticipated goals of clinical management. Considerations for application of ERAS care pathways (developed for Breast Reconstruction, Colorectal, Cystectomy, Gynecologic Oncology, Liver, Major Gynecology, Major Head and Neck, and Pancreas surgery) in rural surgical facilities within Alberta include

- Surgical procedure criteria must be met (see the Rationale section in each ERAS Topic).
  - Adult patients scheduled for Breast Reconstruction, Colorectal, Cystectomy, Gynecologic Oncology, Liver, Major Gynecology, Major Head and Neck, or Pancreas surgery who do not meet the inclusion criteria for the ERAS care pathway may still be considered for applicable recommendations of that pathway (see the Recommendations section in each ERAS Topic)
  - Adult patients scheduled for any other type of surgery may be considered for the Enhanced Recovery for All Surgeries, Adult – Inpatient, Ambulatory care pathway
- Clinical expertise (e.g., surgeon, anesthesia and nursing), clinical support services (e.g., nutrition services, pharmacy, physiotherapy, laboratory, diagnostic imaging), and additional resources (e.g., medications, nutritional supplements, sequential compression...
devices, active warming devices) are available for the duration of clinical care from admission to discharge (see the Recommendations section in each ERAS Topic)
  o There must also be site physician and operations leadership, a site team focused on learning and collaboration, and processes and resources to audit outcomes and compliance

**Disposition Planning**

**Discharge**

Prior to patient discharge from the ERAS care pathway, the following should be considered

- Patient is medically stable
- Patient is functioning close to or at pre-operative level for activities of daily living
- Patient is passing gas or stool
- Patient is tolerating solid food
- Patient’s pain is well controlled on oral analgesia
- Patient’s nausea is well controlled with no vomiting
- Patient’s incisions and/or wounds are healing and managed with appropriate wound care products
- Patient is able to self-catheterize, if appropriate
- Patient is able to manage drains, if appropriate

- Discharge medication list and prescription(s) have been provided to patient
- Discharge teaching is complete and a copy has been provided to patient
- Transition Services/Home Care Services have been arranged, if required
- Wound care/negative-pressure wound therapy supplies have been arranged, if required

- Patient has been referred to the following education resources
  o [Your Surgery Journey – Patient Guide](MyHealth.Alberta.ca)
  o [MyHealth.Alberta.ca](Patient Care Webpages including After Surgery and Incision Care After Surgery)
  o [Patient Care Handouts](Patient Care Handouts including Before and After Surgery - Adult - What to Expect at Home)
  o [Patient Care Videos](Patient Care Videos including Before and After Surgery – Preventing Problems After Surgery)

**Outpatient follow-up**

- If applicable, patient to have staples removed in 4 to 7 days by family physician or in surgeon’s clinic
- Patient to follow-up with their surgeon in 4 to 8 weeks

**Analytics**

**Outcome Measure #1**

<table>
<thead>
<tr>
<th>Name of Measure</th>
<th>ERASAlberta coverage rate</th>
</tr>
</thead>
</table>

ERAS Major Gynecology Surgery, Adult – Inpatient, Ambulatory V 1.1
<table>
<thead>
<tr>
<th>Definition</th>
<th>Number of surgeries performed that were verified ERAS surgeries divided by the total surgeries performed that were eligible ERAS surgeries, multiplied by 100. Calculated provincially, by zone, by site.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rationale</td>
<td>Intended to measure the ability of ERASAlberta to provide enhanced recovery after surgery.</td>
</tr>
</tbody>
</table>

**Outcome Measure #2**

<table>
<thead>
<tr>
<th>Name of Measure</th>
<th>ERASAlberta length of stay (LOS) rates</th>
</tr>
</thead>
</table>
| Definition       | Number of surgeries performed that were verified ERAS surgeries and resulted in  
|                  | • acute LOS less than or equal to acute LOS benchmark  
|                  | • ICU LOS less than or equal to ICU LOS benchmark  
|                  | • readmission LOS less than or equal to readmission LOS benchmark  
|                  | • total LOS less than or equal to total LOS benchmark  
|                  | divided by the total surgeries performed that were verified ERAS surgeries, multiplied by 100. Calculated provincially, by zone, by site. |
| Rationale        | Demonstrates how ERAS impacts patient care by decreasing post-operative complications and accelerating recovery, thereby allowing for earlier discharge. |

**Outcome Measure #3**

<table>
<thead>
<tr>
<th>Name of Measure</th>
<th>ERASAlberta readmission rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definition</td>
<td>Number of surgeries performed that were verified ERAS surgeries and resulted in greater than or equal to 1 unplanned readmission to acute care within 30 days of discharge date divided by the total surgeries performed that were verified ERAS surgeries, multiplied by 100. Calculated provincially, by zone, by site.</td>
</tr>
<tr>
<td>Rationale</td>
<td>Demonstrates how ERAS impacts patient care by decreasing post-operative complications and accelerating recovery, thereby reducing the risk of readmission.</td>
</tr>
</tbody>
</table>

**Outcome Measure #4**

<table>
<thead>
<tr>
<th>Name of Measure</th>
<th>ERASAlberta compliance rates</th>
</tr>
</thead>
</table>
| Definition       | Number of surgeries performed that were verified ERAS surgeries in which specific  
|                  | • ERAS pre-operative care  
|                  | • ERAS intra-operative care  
|                  | • ERAS post-operative care  
|                  | was provided in compliance with ERASAlberta recommendations divided by the total surgeries performed that were verified ERAS surgeries, multiplied by 100. Calculated by site. |
| Rationale        | Compliance with ERASAlberta recommendations is an indicator of the appropriateness of the ERAS care pathway in achieving desired patient outcomes. |
References


Additional Information

AHS Enhanced Recovery after Surgery (ERAS)
www.ahs.ca/ERAS

AHS Knowledge Resource Service ERAS Subject Guide: Surgery Subject Guide
https://krs.libguides.com/surgery/eras
AHS Pre-Operative Fasting and Carbohydrate Loading Prior to Surgical Interventions - Adults

AHS Provincial Clinical Knowledge Topic: Advance Care Planning and Goals of Care
Designations, All Ages – All Locations

The AHS Provincial Clinical Knowledge Topic: Perioperative Management of Patients with Diabetes Mellitus, Adult – Inpatient

AHS Provincial Clinical Knowledge Topic: VTE Prophylaxis, Adult – Inpatient
(link to be added once available)

AHS Recommended Drug Regimens for Surgical Prophylaxis in Adult Patients

AHS Safe Surgery Checklist

AHS Safe Surgery Checklist Policy

AHS Use of Aprepitant (Emend®) for Prevention of Postoperative Nausea and Vomiting (PONV) in Adults

AHS Venous Thromboembolism Prophylaxis Guideline

AHS Venous Thromboembolism Prophylaxis Policy

AHS Weight-Band Dosing for Subcutaneous Tinzaparin or Enoxaparin for Venous Thromboembolism (VTE) Prophylaxis in Acute Care Adult Inpatients
(please see AHS VTE Prophylaxis Weight-Band Table on the AHS internal website)

Bugs & Drugs
http://www.bugsanddrugs.org/

Canadian Nutrition Screening Tool (CNST)

Choosing Wisely Canada: Drop the Pre-Op Toolkit
https://choosingwiselycanada.org/perspective/preop-toolkit/

Choosing Wisely Canada Recommendations and Resources, by Specialty
https://choosingwiselycanada.org/recommendations/

Eating and Drinking Before Surgery: Patient Instructions
https://myhealth.alberta.ca/alberta/Pages/Your-Surgery-Resources.aspx

MyHealth.Alberta.ca Health Information and Tools, Patient Care Handouts
https://myhealth.alberta.ca/health/aftercareinformation/Pages/default.aspx

MyHealth.Alberta.ca Health Information and Tools, Surgery – Incision Care After Surgery

MyHealth.Alberta.ca Health Information and Tools, Surgery – What to Expect
https://myhealth.alberta.ca/health/Pages/conditions.aspx?hwid=tw9795

MyHealth.Alberta.ca Patient Care Videos including Before and After Surgery: ERAS – Your Surgery Journey (videos 1 – 14)

Safer Healthcare Now! Prevent Surgical Site Infections

Your Surgery Journey – Patient Guide
https://myhealth.alberta.ca/YourSurgeryJourney
Appendix A – ERAS Nutrition Working Group Consensus: Juice as Carbohydrate Loading Products

Drawing from the best practices around the world, ERAS has been implemented in Alberta to enhance perioperative patient care, support patient recovery and reduce health care costs. Carbohydrate (CHO) loading is one of about 24 ERAS protocol elements and is an integral part of the preoperative care process. The main purpose is to attenuate postoperative insulin resistance, which contributes to negative nitrogen balance, leading to muscle mass loss and reduced muscle strength. In addition, CHO loading hinders preoperative stress, hunger and thirst in surgical patients. According to ERAS guidelines, CHO loading involves ingestion of clear fluids that contain complex CHOs, mostly of maltodextrins. These products have been extensively researched and are recommended for preoperative use by the ERAS guidelines.

ERAS and The European Society of Anaesthesiology Guidelines recommend the ingestion of CHO-rich beverages that are specifically developed for preoperative consumption up to two hours before surgery. No specific guidelines are given regarding the type and/or brand of products to be used; however, it is suggested that not all CHOs are safe. Gastric emptying is the major concern preoperatively, therefore beverages with lower osmolality assumed to be safer for preoperative consumption. In addition, it was suggested that the insulin response to the beverage should reach 60 μIU/mL to achieve appropriate fed state that is believed to improve postoperative insulin resistance. All research that has been done involves commercial products. The preoperative CHO loading product most often studied is Nutricia Preop® that contains 12.5% CHO from maltodextrin and has low osmolality (260 mOsm/kg H2O) to induce faster gastric emptying. Nutricia Preop®, is in liquid form and is only available in Europe. PREcovery™ is a new CHO-containing product commercially available in Canada that contains 12.5% CHO from maltodextrin and has low osmolality (114 mOsmol/kgH2O). Although it is a potential commercial product that can be used for ERAS, more studies are needed to explore the effectiveness of PREcovery™. As well, this product is in powder form and needs to be mixed with 400 mL of water, which may lessen the practicality of using this product for ERAS. Decisions will need to be made on access and availability of the product, who will prepare the product, the process of preparing this product for patient safety and who will cover the product’s cost.

Because of the limited availability and research of commercial CHO-containing products in Canada, the ERAS Nutrition Working Group (WG) continues to recommend the use of apple juice and cranberry cocktail juice. Although there are no published studies on the safety of juice as a preoperative CHO-loading product, no adverse effects have been reported on using juice for this purpose since ERAS was first implemented in Alberta in 2013. As well, based on an ERAS nutrition and environmental scan, Canadian sites using juice as the ERAS preoperative CHO-loading product reported no adverse effects.

The ERAS Nutrition WG recommendation continues to be based on the following criteria: availability, palatability, clinical considerations, volume needed, ease and process of administration, cost of product, infection control and simplicity (for patient use and nurses and physicians to discuss with and teach patients). Juice meets most of the beverage criteria as it is conveniently available and palatable, can be used at home or in hospital for minimal cost.
compared to CHO-containing products, is already pre-packaged, simple to consume, and easy for physicians and health professionals to discuss with and teach patient as part of ERAS preoperative teaching. However, this WG’s consensus may be updated once new research and products that meet the criteria are available.

References:


Acknowledgements

We would like to acknowledge the contributions of the clinicians who participated in the development of this topic. Your expertise and time spent are appreciated.

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Zone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surgery Knowledge Lead</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Anastasio Salazar</td>
<td>Transplant Surgeon</td>
<td>Provincial</td>
</tr>
<tr>
<td><strong>Topic Lead</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Chandrew Rajakumar</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>Calgary</td>
</tr>
<tr>
<td><strong>Working Group Members</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Jackie Thurston</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>Calgary</td>
</tr>
<tr>
<td>Dr. Kevin Wiebe</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>Central</td>
</tr>
<tr>
<td>Dr. Michael Bow</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>Edmonton</td>
</tr>
<tr>
<td>Dr. Priya Patel</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>Edmonton</td>
</tr>
<tr>
<td>Dr. Brian Muir</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>North</td>
</tr>
<tr>
<td>Dr. Jaye Malach</td>
<td>Obstetrics &amp; Gynecology, Surgeon</td>
<td>South</td>
</tr>
<tr>
<td>Alison Nelson</td>
<td>ERAS Provincial Manager</td>
<td>Provincial</td>
</tr>
<tr>
<td>Lynn Nicholson</td>
<td>ERAS Provincial Project Manager</td>
<td>Provincial</td>
</tr>
<tr>
<td>Pat Trudeau</td>
<td>ERAS Nurse Instructor</td>
<td>Calgary</td>
</tr>
<tr>
<td>Christine Fantuz</td>
<td>ERAS Nurse Instructor</td>
<td>Calgary</td>
</tr>
<tr>
<td>Karen Jaretzke</td>
<td>ERAS Nurse Instructor</td>
<td>Edmonton</td>
</tr>
<tr>
<td>Sheena Morton</td>
<td>ERAS Nurse Instructor</td>
<td>Edmonton</td>
</tr>
<tr>
<td>Miranda Klein</td>
<td>ERAS Nurse Instructor</td>
<td>Edmonton</td>
</tr>
<tr>
<td>Stacey Ginther</td>
<td>Pharmacist</td>
<td>Provincial</td>
</tr>
<tr>
<td><strong>Clinical Support Services</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>James Wesenberg</td>
<td>on behalf of Laboratory Services – Provincial Networks</td>
<td>Provincial</td>
</tr>
<tr>
<td>Bernice Lau &amp; Mark Buller</td>
<td>on behalf of Diagnostic Imaging Services</td>
<td>Provincial</td>
</tr>
<tr>
<td>Carlota Basualdo-Hammond</td>
<td>on behalf of Nutrition &amp; Food Services</td>
<td>Provincial</td>
</tr>
<tr>
<td>Taciana Pereira &amp; Lesley Beique</td>
<td>Pharmacy Information Management Governance Committee (PIM-GC) on behalf of Pharmacy Services</td>
<td>Provincial</td>
</tr>
<tr>
<td><strong>Clinical Informatics Lead</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Candice Healey</td>
<td>Registered Nurse</td>
<td>Provincial</td>
</tr>
</tbody>
</table>

Additional Contributors

Thank you to all provincial stakeholders who participated in the review process for this topic. Your time spent reviewing the knowledge topics and providing valuable feedback is appreciated.

For questions or feedback please contact ClinicalKnowledgeTopics@ahs.ca